Quantitation in bioluminescence imaging by correction of tissue absorption for experimental oncology.
OBJECTIVE
We have developed a method of quantitation for correcting tissue absorption in in vivo bioluminescence imaging (BLI).


METHODS
Variations of luciferin emission spectrum were determined and were related to photon absorption to determine a correction curve. This was validated by combining BLI with tomoscintigraphy and tomodensitometry, which were applied to a lymphoma model.


RESULTS
Tissue absorption affects luciferin emission spectrum, mainly for wavelengths less than 620 nm. So, we have selected two filters bordering 620 nm to quantify spectral modifications. A significant correlation was obtained between the spectral analysis and the percentage of transmitted light through tissues (R(2) = 0.97). On a disseminated tumour model, we have shown that such a methodology is of great interest to compare bioluminescent signals and to get more accurate quantitative data about tumour proliferation.


CONCLUSIONS
Spectral analysis allows improved quantitation of BLI and could be of value to perform pharmacological studies and to follow tumour progression in models with tumours evolving in different locations.
Pesnel
Sabrina
S
UPS no 44 TAAM-CIPA, CNRS, Orléans, France.
Pillon
Arnaud
A
Créancier
Laurent
L
Guilbaud
Nicolas
N
Bailly
Christian
C
Kruczynski
Anna
A
Lerondel
Stéphanie
S
Le Pape
Alain
A
D000042:Absorption; D000818:Animals; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D049454:Firefly Luciferin / Q000378:metabolism; D006801:Humans; D008027:Light; D008163:Luminescent Measurements / Q000379:methods*; D008223:Lymphoma / Q000175:diagnosis; D051379:Mice; D057054:Molecular Imaging / Q000379:methods*; D009374:Neoplasms, Experimental / Q000175:diagnosis*; D009928:Organ Specificity; D015203:Reproducibility of Results; D013050:Spectrometry, Fluorescence
D049454:Firefly Luciferin